title: Pathophysiology of congenital diaphragmatic hernia. VIII: Inhaled nitric oxide requires exogenous surfactant therapy in the lamb model of congenital diaphragmatic hernia.
abstract: The pathophysiology of the lamb model of congenital diaphragmatic hernia (CDH) involves pulmonary hypoplasia, pulmonary hypertension, and surfactant deficiency. Inhaled nitric oxide (NO) is a highly selective pulmonary vasodilator. The aim of this study was to determine the effects of inhaled NO on pulmonary gas exchange, acid-base balance, and pulmonary pressures in a lamb model of CDH with or without exogenous surfactant therapy. At the gestational age of 78 days (full term, 145 days) 11 lamb fetuses had a diaphragmatic hernia created via a left thoracotomy and then were allowed to continue development in utero. After cesarean section, performed at term, six lambs received exogenous surfactant therapy (50 mg/kg, Infasurf) and five served as controls. All animals were pressure-ventilated for 30 minutes and then received 80 ppm of inhaled NO at an F1O2 of .9 for a 10-minute interval. Compared with the control lambs, the lambs with exogenous surfactant therapy had higher pH (7.17 +/- .06 v 6.96 +/- .07; P < .05), lower PCO2 (73 +/- 8 v 122 +/- 20, p < .05), and higher PO2 (153 +/- 38 v 50 +/- 23; P < .05). In control CDH lambs (without surfactant), inhaled NO did not improve pH, PCO2, or PO2, or decrease pulmonary artery pressure. In CDH lambs given exogenous surfactant, NO decreased pulmonary artery pressures (42 +/- 4 v 53 +/- 5; P < .005) and further improved PCO2 and PO2. NO also made the difference between pulmonary and systemic artery pressures more negative in the surfactant-treated lambs (-15 +/- 4 v -2.3 +/- 2.4; P < .005).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Buffalo Institute of Fetal Therapy (BIFT), Children's Hospital of Buffalo, State University of New York at Buffalo 14222.
authors.forename: H L
authors.initials: HL
authors.lastname: Karamanoukian
authors.forename: P L
authors.initials: PL
authors.lastname: Glick
authors.forename: D T
authors.initials: DT
authors.lastname: Wilcox
authors.forename: J E
authors.initials: JE
authors.lastname: Rossman
authors.forename: B A
authors.initials: BA
authors.lastname: Holm
authors.forename: F C
authors.initials: FC
authors.lastname: Morin
mesh_terms: D000280:Administration, Inhalation; D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D001794:Blood Pressure; D015199:Extracorporeal Membrane Oxygenation; D005260:Female; D006548:Hernia, Diaphragmatic / Q000503:physiopathology* / Q000628:therapy; D065630:Hernias, Diaphragmatic, Congenital; D006863:Hydrogen-Ion Concentration; D009569:Nitric Oxide / Q000627:therapeutic use; D011247:Pregnancy; D011651:Pulmonary Artery / Q000503:physiopathology*; D011659:Pulmonary Gas Exchange / Q000502:physiology*; D011663:Pulmonary Surfactants / Q000627:therapeutic use; D012756:Sheep
chemical_list: D011663:Pulmonary Surfactants; D009569:Nitric Oxide